Merck & Co. Inc. share price logo

Merck & Co. Inc.

NASDAQ: MRK

Mega Cap

$113.87

-1.57

(-1.36%)

as on

Merck & Co. Inc. Stock Performance

as on June 19, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $111.57
    $115.01
    downward going graph

    2.02%

    Downside

    1.00%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $76.66
    $125.14
    downward going graph

    32.68%

    Downside

    9.90%

    Upside

    downward going graph

Merck & Co. Inc. share price movements today

Previous Close
$115.44
Open
$115.01
Volume
14.5M
Day's Low - High
$111.57 - $115.01
52 Week Low - High
$76.66 - $125.14

Merck & Co. Inc. Historical Returns

1 Month Return
-0.32 %
3 Month Return
-0.29 %
1 Year Return
+ 43.61 %
3 Year Return
+ 4.16 %
5 Year Return
+ 48.64 %

Merck & Co. Inc. Stock Fundamentals & Key Indicators

Check Merck & Co. Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$285.1B

EPS (TTM)

2.7366

Dividend Yield

2.85%

Quarterly Earnings Growth YOY

-0.19%

PE Ratio (TTM)

32.52

Industry PE ratio

24.841428571428573

PEG Ratio

5.3681

EBITDA

29.5B

Revenue (TTM)

65.8B

Profit Margin

13.59%

Return On Equity TTM

18.94%

Merck & Co. Inc. Stock Valuation

Track how Merck & Co. Inc. P/E has moved over time to understand its valuation trends.

Merck & Co. Inc. in the last 5 years

  • Overview

  • Trends

Lowest (9.52x)

September 30, 2025

Industry (24.84x)

June 19, 2026

Today (32.52x)

June 19, 2026

Highest (69.20x)

December 31, 2023

LowHigh

Today’s Price to Earnings Ratio: 32.52x

Merck & Co. Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Merck & Co. Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Merck & Co. Inc. image
Merck & Co. Inc.
BUY$285.1B48.64%32.5213.59%2.85%
Eli Lilly & Co. image
Eli Lilly & Co.
BUY$991.6B402.66%39.4734.99%0.5599999999999999%
AstraZeneca PLC image
AstraZeneca PLC
BUY$271.4B199.69%26.3217.19%1.7999999999999998%
ABBVIE INC. image
ABBVIE INC.
BUY$390.9B91.38%107.925.79%3.0300000000000002%
Johnson & Johnson image
Johnson & Johnson
BUY$563.8B41%27.1421.83%2.21%

Stock Returns calculator for Merck & Co. Inc. Stock including INR - Dollar returns

The Merck & Co. Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Merck & Co. Inc. investment value today

Current value as on today

₹1,56,434

Returns

₹56,434

(+56.43%)

Returns from Merck & Co. Inc. Stock

₹43,612 (+43.61%)

Dollar Impact

₹12,822 (+12.82%)

Analyst Recommendation on Merck & Co. Inc. Stock

Based on 31 analysts

BUY

87.10%

Buy

12.90%

Hold

0.00%

Sell

Based on 31 analysts, 87.1% of analysts recommend a 'BUY' rating for Merck & Co. Inc.. Average target price of $129.74

Merck & Co. Inc. Share Price Target

Get share price movements and forecasts by analysts on Merck & Co. Inc..

What analysts predicted

12.23%UPSIDE

Target Price

$129.74

Current Price

$113.87

Analyzed by

31 Analysts

Target

$129.74

Merck & Co. Inc. target price $129.74, a slight upside of 12.23% compared to current price of $113.87. According to 31 analysts rating.

Indian Investors' Interest in Merck & Co. Inc. Stock

Investment in Merck & Co. Inc. Shares on INDmoney has dropped by -5.65% in the last 30 days, indicating reduced investment activity.

Time period: to

Change:-5.65% versus previous 30 day period

Search interest for Merck & Co. Inc. Stock has increased by 48% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:48% versus previous 30 day period

Merck & Co. Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
14,630
15,775
16,112
16,657
15,624
15,619
15,800
17,183
16,324
16,286
Gross Profit
10,718
12,235
12,367
12,577
11,796
11,734
11,953
12,989
11,507
13,342
Operating Income
-1,713
5,760
6,128
3,984
4,348
6,710
6,359
7,463
6,160
-1,884
EBITDA
-772
6,744
7,448
5,606
5,695
7,315
6,360
8,144
6,297
-2,022
Interest Expense
310
303
310
330
328
313
305
327
411
479
Depreciation
964
984
1,132
1,186
1,197
1,099
1,119
1,154
2,466
1,512
Income Before Tax
-2,046
5,670
6,006
4,090
4,170
5,903
4,999
6,745
3,420
-3,534
Income Tax Expense
-820
-
545
929
426
818
571
958
458
709
Net Income
-1,226
4,762
5,455
3,157
3,743
5,079
4,427
5,785
2,963
-4,240
Net Profit Margin
-8.38%
30.19%
33.86%
18.95%
23.96%
32.52%
28.02%
33.67%
18.15%
-26.03%

Merck & Co. Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
39,807
40,122
42,294
39,121
41,518
48,704
59,283
60,115
64,168
64,926
Gross Profit
25,777
27,210
28,785
27,105
27,900
35,078
41,872
43,989
48,975
46,731
Operating Income
5,499
6,797
8,931
7,926
5,548
13,199
18,282
2,954
20,221
23,486
EBITDA
10,823
11,951
13,992
11,374
10,180
17,899
21,315
6,907
25,706
28,262
Interest Expense
693
754
772
893
831
806
962
1,146
1,271
1,357
Depreciation
-
4,637
4,519
3,652
3,625
3,214
3,909
3,800
4,499
5,838
Income Before Tax
4,659
6,521
8,701
7,171
5,863
13,879
16,444
1,889
19,936
21,067
Income Tax Expense
718
4,103
2,508
1,565
1,340
1,521
1,918
1,512
2,803
2,804
Net Income
3,920
2,394
6,220
9,843
7,067
13,049
14,519
365
17,117
18,254
Net Profit Margin
9.85%
5.97%
14.71%
25.16%
17.02%
26.79%
24.49%
0.61%
26.68%
28.12%

Merck & Co. Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
4,767
5,461
3,161
3,744
5,085
4,429
5,787
2,963
-4,243
Operating Cash Flow
3,090
5,637
9,291
3,450
2,500
3,293
7,822
2,857
3,918
Investing Cash Flow
-1,376
-1,069
-3,845
-1,444
-1,487
-770
-283
-11,201
-10,210
Financing Cash Flow
-2,814
1,216
-2,425
-3,009
-5,755
-3,556
2,638
4,751
-2,981
Change in Cash
-1,238
5,702
3,315
-1,370
-4,586
-659
10,187
-3,514
-9,292

Merck & Co. Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
2,418
6,193
9,777
7,082
12,358
14,526
365
17,133
18,254
Operating Cash Flow
6,447
10,922
13,440
10,253
14,109
19,095
13,006
21,468
16,472
Investing Cash Flow
2,679
4,314
-2,629
-9,443
-16,555
-4,960
-14,083
-7,734
-13,741
Financing Cash Flow
-10,006
-13,160
-8,861
-2,832
2,593
-9,119
-4,810
-7,032
-1,922
Change in Cash
-423
1,871
1,967
-1,769
14
4,606
-5,864
6,409
1,372

Mutual Funds that own Merck & Co. Inc. Stock

Check out the Mutual Funds with significant holdings in Merck & Co. Inc..

Global Institutional Holdings in Merck & Co. Inc.

Funds
Holdings
Morgan Stanley - Brokerage Accounts
1.93%
Goldman Sachs Group Inc
0.74%
NORGES BANK
1.54%
The Goldman Sachs Group Inc
0.82%
Wellington Management Company LLP
3.41%
See all

Merck & Co. Inc. News & Key Events

  • img

    Today's Timeline - 18 June

    Thu, 04:15 PM

    -

    Merck receives FDA approval for CAPVAXIVE in children aged 2-17 at increased risk for pneumococcal disease.

Insights on Merck & Co. Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Eli Lilly & Co. has given 138.4% return, outperforming this stock by 136.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, AstraZeneca PLC has given 150.1% return, outperforming this stock by 106.1%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Merck & Co., Inc. has experienced a decline in its net profit over the last three quarters. The profit fell from $5.78 billion to -$4.24 billion. This represents an average decrease of 145.9% in profit each quarter.

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Merck & Co., Inc. has experienced a decline in revenue for the past three quarters. The revenue fell from $17.18 billion to $16.28 billion, resulting in an average decrease of 2.6% each quarter.

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, MRK stock has moved down by -4.4%

About Merck & Co. Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
OrganisationMerck & Co. Inc.
Headquarters126 East Lincoln Avenue, Rahway, NJ, United States, 07065
IndustryDrug Manufacturers - General
CEOMr. Robert M. Davis J.D.
E-voting on sharesClick here to vote

Key Management of Merck & Co. Inc.

Name

Title

Mr. David Michael Williams

Executive VP and Chief Information & Digital Officer

Mr. Peter Dannenbaum

Vice President of Investor Relations

Mr. Chirfi Guindo

Executive Vice President of Strategic Access, Policy & Communications

Ms. Betty D. Larson

Executive VP & Chief Human Resources Officer

Mr. Robert M. Davis J.D.

Chairman, President & CEO

Dr. Dean Y. Li M.D., Ph.D.

Executive VP & President of Merck Research Laboratories

Mr. Dalton E. Smart III

Senior VP of Finance, Principal Accounting Officer & Global Controller

Ms. Caroline A. Litchfield

Executive VP & CFO

Ms. Jennifer L. Zachary J.D.

Executive VP & General Counsel

Mr. Richard R. DeLuca Jr.

Executive VP & President of Merck Animal Health

FAQs

What is Merck & Co. Inc. share price today?

Merck & Co. Inc. share price today is $113.87 as on at the close of the market. Merck & Co. Inc. share today touched a day high of $115.01 and a low of $111.57.

What is the 52 week high and 52 week low for Merck & Co. Inc. share?

Merck & Co. Inc. share touched a 52 week high of $125.14 on and a 52 week low of $76.66 on . Merck & Co. Inc. stock price today i.e. is closed at $113.87,which is 9.01% down from its 52 week high and 48.54% up from its 52 week low.

What is Merck & Co. Inc.'s market capitalisation today?

Merck & Co. Inc. market capitalisation is $0.29T as on .

How to invest in Merck & Co. Inc. Stock (MRK) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Merck & Co. Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Merck & Co. Inc. Shares that will get you 0.0132 shares as per Merck & Co. Inc. share price of $113.87 per share as on June 19, 2026 at 8:46 am IST.

What is the minimum amount required to buy Merck & Co. Inc. Stock (MRK) from India?

Indian investors can start investing in Merck & Co. Inc. (MRK) shares with as little as ₹94.31 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹943.10 in Merck & Co. Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Merck & Co. Inc. share’s latest price of $113.87 as on June 19, 2026 at 8:46 am IST, you will get 0.0878 shares of Merck & Co. Inc.. Learn more about fractional shares .

What are the returns that Merck & Co. Inc. has given to Indian investors in the last 5 years?

Merck & Co. Inc. stock has given 48.64% share price returns and 27.24% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?